A study of GSK1120212 compared with chemotherapy in patients with BRAF mutation positive advanced or metastatic melanoma

Update Il y a 4 ans
Reference: EUCTR2010-022838-85

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective for this study is to establish the superiority of GSK1120212 over chemotherapy with respect to progression-free survival for subjects with advanced/metastatic BRAF V600E mutation-positive melanoma without a history of prior brain metastases.


Inclusion criteria

  • Advanced or metastatic BRAF V600E/K mutation-positive melanoma